11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.

          Related collections

          Author and article information

          Journal
          Lancet Oncol.
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          May 2018
          : 19
          : 5
          Affiliations
          [1 ] Humanitas Cancer Center, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
          [2 ] Service d'Oncologie Médicale, CHRU Saint Eloi, Montpellier, France.
          [3 ] Department of Internal Medicine III, Section of Gastroenterology/Hepatology, Medizinische Universitaet Wien, Wien, Austria; Department of Internal Medicine and Gastroenterology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
          [4 ] Centre Eugène Marquis et CH Saint Malo, Rennes, France.
          [5 ] Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.
          [6 ] Service des Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Lille Cedex, France.
          [7 ] Oncologia Medica, AO Papa Giovanni XXIII Hospital, Bergamo, Italy.
          [8 ] IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
          [9 ] Department of Oncology and Medical Oncology Unit, AO G Rummo Hospital, Benevento, Italy.
          [10 ] Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Center for Applied Biomedical Research, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
          [11 ] Department of Gastro-Intestinal Surgery and Liver Transplantation, University of Milan, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
          [12 ] University of Washington School of Medicine, Seattle, WA, USA.
          [13 ] Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
          [14 ] Department of Oncology, Santa Maria del Prato Hospital, Feltre, Italy.
          [15 ] Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
          [16 ] Solid Tumor Medical Oncology, McCain Centre for Pancreatic Cancer, University Health Network, Princess Margaret Cancer Center at the OPG, Toronto, ON, Canada.
          [17 ] Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
          [18 ] Universitätsklinikum Frankfurt, Medizinische Klinik 1, Frankfurt, Germany.
          [19 ] Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
          [20 ] Humanitas Cancer Center, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
          [21 ] Institute for Advanced Biosciences-INSERM U1209, CNRS UMR 5309 and Department of Hepatogastroenterology Université Grenoble-Alpes, Grenoble, France; Clinique Universitaire d'Hépato-gastroentérologie, Pôle Digidune, Centre Hospitalier Universitaire Grenoble-Alpes, La Tronche, France.
          [22 ] Department of Internal Medicine III, Section of Gastroenterology/Hepatology, Medizinische Universitaet Wien, Wien, Austria.
          [23 ] ArQule Inc, Burlington, MA, USA.
          [24 ] Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
          [25 ] Humanitas Cancer Center, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
          [26 ] Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address: jbruix@clinic.cat.
          Article
          S1470-2045(18)30146-3
          10.1016/S1470-2045(18)30146-3
          29625879
          c037eb8f-e875-41ae-b3c7-a45295c80b8e
          History

          Comments

          Comment on this article